Recent News

• 04.24.2025 - Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry
• 04.14.2025 - Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results
• 04.04.2025 - Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
• 03.31.2025 - Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia
• 03.31.2025 - Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025
• 03.20.2025 - Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules
• 03.17.2025 - Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules
• 03.11.2025 - Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum
• 03.11.2025 - Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
• 03.05.2025 - Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

Recent Filings

• 04.09.2025 - DEF 14A Other definitive proxy statements
• 04.09.2025 - ARS Annual Report to Security Holders
• 04.09.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.04.2025 - EX-99.1 EX-99.1
• 04.04.2025 - 8-K Current report
• 03.06.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors